Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biocryst
Biotech
CSL links drug to rare disease benefits, plans global filings
Phase 3 data on CSL’s garadacimab in a rare disease suggest the antibody may have an edge over Takeda’s Takhzyro in terms of efficacy and convenience.
Nick Paul Taylor
Feb 27, 2023 10:15am
BioCryst hits another hurdle, delays trial after pipeline culls
Feb 23, 2023 11:33am
BioCryst scraps $200M offering after seeing share price slide
Aug 11, 2021 7:35am
BioCryst starts COVID-19 trial of broad-spectrum antiviral
Apr 10, 2020 7:55am
BioCryst says oral drug works for HAE attacks
Sep 4, 2018 10:15am
BioCryst stockholders call off merger with Idera Pharmaceuticals
Jul 11, 2018 10:20am